Evidence map›Paper›PMID 28296000›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017

Novel Application of Localized Nanodelivery of Anti-Interleukin-6 Protects Organ Transplant From Ischemia-Reperfusion Injuries.

Z Solhjou, M Uehara, B Bahmani, O H Maarouf, T Ichimura, C R Brooks, W Xu, M Yilmaz, A Elkhal, S G Tullius and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  3. Inhibition of CD154:CD11b interactions using a novel nanotherapeutic improves allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Targeting IL-6 to prevent cardiac allograft rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Review
  9. Nanotherapeutics in transplantation: How do we get to clinical implementation?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Z SolhjouTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
M UeharaTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
B BahmaniTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
O H MaaroufTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
T IchimuraRenal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
C R BrooksRenal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
W XuTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
M YilmazTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
A ElkhalDivision of Transplant Surgery and Transplantation Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
S G TulliusDivision of Transplant Surgery and Transplantation Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
I GuleriaTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
M M McGrathTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
R AbdiTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · USHarvard University · US

Funding

Organ Design and Engineering Training Program (ODET Program)T32EB016652 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2014 to 2023
$3.5M
Protection of organ transplant from ischemia reperfusion injuriesR01AI126596 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2016 to 2020
$2.6M
Ischemia-reperfusion injury in transplantation: novel cytoprotection strategiesR01AI091930 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2011 to 2015
$2.1M
The novel role of the PI3Kγ and δ pathways in alloimmunityR56AI123270 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2016 to 2016
$404k
NIAID NIH HHS R01 AI091930NIAID NIH HHS R01 AI126596NIAID NIH HHS R56 AI123270NIBIB NIH HHS T32 EB016652
6 · The paper itself

Abstract

Ischemia-reperfusion injury (IRI) evokes intragraft inflammatory responses, which markedly augment alloimmune responses against the graft. Understanding the mechanisms underlying these responses is fundamental to develop therapeutic regimens to prevent/ameliorate organ IRI. Here, we demonstrate that IRI results in a marked increase in mitochondrial damage and autophagy in dendritic cells (DCs). While autophagy is a survival mechanism for ischemic DCs, it also augments their production of interleukin (IL)-6. Allograft-derived dendritic cells (ADDCs) lacking autophagy-related gene 5 (Atg5) showed higher death rates posttransplantation. Transplanted ischemic hearts from CD11cCre/Atg5 conditional knockout mice showed marked reduction in intragraft expression of IL-6 compared with controls. To antagonize the effect of IL-6 locally in the heart, we synthesized novel anti-IL-6 nanoparticles with capacity for controlled release of anti-IL-6 over time. Compared with systemic delivery of anti-IL-6, localized delivery of anti-IL-6 significantly reduced chronic rejection with a markedly lower amount administered. Despite improved allograft histology, there were no changes to splenic T cell populations, illustrating the importance of local IL-6 in driving chronic rejection after IRI. These data carry potential clinical significance by identifying an innovative, targeted strategy to manipulate organs before transplantation to diminish inflammation, leading to improved long-term outcomes.

Indexed as

Drug Delivery SystemsInterleukin-6 InhibitorsAnimalsAntibodies, MonoclonalAutophagy-Related Protein 5Cells, CulturedDendritic CellsGraft RejectionGraft SurvivalHeart TransplantationInflammationMiceMice, Inbred C57BLMice, KnockoutNanoparticlesReperfusion InjuryAntibodies, MonoclonalAtg5 protein, mouseAutophagy-Related Protein 5Interleukin-6 Inhibitorsanimal models: murinebasic (laboratory) research/scienceimmunosuppression/immune modulationischemia reperfusion injury (IRI)

Identifiers

PMID28296000
PMCPMC5573642
OpenAlexW2593471956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.